Role of endogenous secretory RAGE (esRAGE) in defending against plaque formation induced by oxidative stress in type 2 diabetic patients

Atherosclerosis

Volumn 226, Issue 1, 2013, Pages 252-257

  Piarulli, Francesco ^a   Lapolla, Annunziata ^a   Ragazzi, Eugenio ^a   Susana, Angela ^a   Sechi, Annalisa ^a   Nollino, Laura ^a   Cosma, Chiara ^a   Fedele, Domenico ^a   Sartore, Giovanni ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Atherosclerotic plaque; EsRAGE; Oxidative stress; Type 2 diabetes

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ALPHA TOCOPHEROL; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ENDOGENOUS SECRETORY RECEPTOR FOR ADVANCED GLYCATION END PRODUCT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ABDOMINAL AORTA; ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY; COLOR ULTRASOUND FLOWMETRY; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; ILIAC ARTERY; LEG ARTERY; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL;

AGED; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PLAQUE, ATHEROSCLEROTIC; RECEPTORS, IMMUNOLOGIC;

EID: 84871383086     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.10.050     Document Type: Article

References (38)

1. Vlassara H., Bucala R., Striker L. Pathogenic effect of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 1994, 2:138-151.
2. Basta G., Schmidt A.M., De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004, 63:582-592.
3. Goldin A., Beckman J.A., Schmidt A.M., Creager M.A. Advanced glycation end products sparking the development of diabetic vascular injury. Circulation 2006, 114:597-605.
4. Schmidt A.M., Hofmann M., Taguchi A., Yan S.D., Stern D.M. RAGE: a multiligand receptor contributing to the cellular response in diabetic vasculopathy and inflammation. Semin Thromb Hemost 2000, 26:485-493.
5. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis 2008, 196:9-21.
6. Coughlan M.T., Thorburn D.R., Penfold S.A., et al. RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol 2009, 20:742-752.
7. Kislinger T., Fu C., Huber B., et al. N(epsilon)-carboxymethyllysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 1999, 44:31740-31749.
8. Schleicher E.D., Wagner E., Nerlich A.G. Increased accumulation of glycoxidation product carboxymethyllysine in human tissues in diabetes and aging. J Clin Invest 1997, 99:457-468.
9. Yonekura H., Yamamoto Y., Sakurai S., et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003, 370:1097-1109.
10. Vazzana N., Santilli F., Cuccurullo C., Davì G. Soluble forms of rage in internal medicine. Intern Emerg Med 2009, 4:389-401.
11. Nawroth P.P., Stern D.M. Soluble forms of rage: an index of vascular stress? A commentary on " soluble rage in type 2 diabetes: association with oxidative stress" Free Radic Biol Med 2007, 43:506-510.
12. Humpert P., Djuric Z., Kopf S., et al. sRAGE but not esRAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol 2007, 6:9-13.
13. Devangelio E., Santilli F., Formoso G., et al. Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radic Biol Med 2007, 43:511-518.
14. Piarulli F., Sartore G., Ceriello A., et al. Relationship between glyco-oxidation, antioxidant status and microalbuminuria in type 2 diabetic patients. Diabetologia 2009, 52:1419-1425.
15. Katakami N., Matsuhisa M., Kaneto H., et al. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care 2005, 28:2716-2721.
16. Koyama H., Shoji T., Yokoyama H., et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005, 25:2587-2593.
17. Jones G., Lim Ee-Mun The National Kidney Foundation guideline on estimation of the glomerular filtration rate. Clin Biochem Rev 2003, 24:95-98.
18. Wagner Z., Wittmann I., Mazák I., et al. N(epsilon)-(carboxymethyl)-lysine levels in type 2 diabetic patients: role of renal function. Am J Kidney Dis 2001, 38:785-791.
19. Makita Z., Vlassara H., Cerami A., Bucala R. Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 1992, 267:5133-5138.
20. Laidman D.L., Hall G.S. Adsorption column chromatography of tocopherols. Methods in enzymology, part C: vitamins and coenzymes 1971, 18:349-356. Academic Press, New York.
21. Zheng Z.J., Sharrett A.R., Chambless L.E., et al. Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis 1997, 131:115-125.
22. Eng J. Sample size estimation: how many individuals should be studied?. Radiology 2003, 227:309-313.
23. Hanley J.A., McNeil B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1992, 143:29-36.
24. Verges B. Lipid modification in type 2 diabetes: the role of LDL and HDL. Fundam Clin Pharmacol 2009, 23:681-685.
25. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
26. Jennings P., Chirico S., Jones A.F., Lunec J., Banett A.H. Vitamin C metabolities and microangiopathy in diabetes mellitus. Diabetes Res 1987, 6:151-154.
27. Ikeda K., Higashi T., Sano H., et al. N (epsilon)-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry 1996, 35:8075-8083.
28. Katakami N., Matsuhisa M., Kaneto H., et al. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. Atherosclerosis 2009, 204:288-292.
29. Yan S.F., Ramasamy R., Schmidt A.M. Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem Pharmacol 2010, 79:1379-1386.
30. Chen G., Cai L., Chen B., et al. Serum level of endogenous secretory receptor for advanced glycation end products and other factors in type 2 diabetic patients with mild cognitive impairment. Diabetes Care 2011, 34:2586-2590.
31. Lu L., Pu L.J., Zhang Q., et al. Increased glycated albumin and decreased esRAGE levels are related to angiographic severity and extent of coronary artery disease in patients with type 2 diabetes. Atherosclerosis 2009, 206:540-545.
32. Peng W.H., Lu L., Hu J., et al. Decreased serum esRAGE level is associated with angiographically determined coronary plaque progression in diabetic patients. Clin Biochem 2009, 42:1252-1259.
33. Levula M., Oksala N., Airla N., et al. Genes involved in systemic and arterial bed dependent atherosclerosis - Tampere Vascular Study. PLoS One 2012, 7(4):e33787.
34. Lapolla A., Piarulli F., Sartore G., et al. Advanced glycation end products and antioxidant status in type 2 diabetic patients with and without peripheral artery disease. Diabetes Care 2007, 30:670-676.
35. Cipollone F., Iezzi A., Fazia M., et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques. Circulation 2003, 108:1070-1077.
36. Yang S.J., Kim S., Hwang S.Y., et al. Association between sRAGE, esRAGE levels and vascular inflammation: analysis with 18F-fluorodeoxyglucose positron emission tomography. Atherosclerosis 2012, 220:402-406.
37. Koyama H., Yamamoto H., Nishizawa Y. RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases. Mol Med 2007, 13:625-635.
38. Colhoun H.M., Betteridge D.J., Durrington P., et al. Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes. An analysis from the CARDS trial. Diabetes 2011, 60:2379-2385.